Objective: To see if modifications to the processing of intravenous immunoglobulin to include a virus inactivation stage alter immunoglobulin G (IgG) resulting in hypotension in patients. Methods: Clinical trials were done involving extensive patient monitoring during infusion: in vitro‐testing for markers of hypotension, and in vivo‐an animal model which closely simulates clinical use. Results: No hypotensive response was seen in the animal model or clinical trial. Conclusions: The production process used does not damage IgG or create vaso‐active kinins as the preparation was free of hypotensive effects.
No takes yet. Share an insight, caveat, or question.
Chidwick et al. (1999) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: